ANP - Interesting general news items in BIO, page-58

“2022 GuidanceSarepta reiterated its revenue guidance for 2022. Management expects total revenues in 2022 to be in the range of $905-$920. The company expects net product revenues for the full year to be in the range of $825-$840 million.”

Ok
Let me be the first .
Many on this thread call my $5 in time :Ridiculous !
Serepta will earn $830million US in 2022 and that’s only in the USA .approx 20% of ambulant boys

If Anp is successful in their DMD trial in Non Ambulant boys and progress to treat Ambulant boys
as well
We are looking at
1) US $500 million
2) Europe $500 mill
Conservative estimate over $1 billion per annum

Calculate earnings per share x10…(conservative)

Thats a great deal more than $5

Now


Let’s look at Limb Girdle
The LG market is as big as Dmd

Then
Let’s look at Long Covid
$ Millions in income

Look in the future to
1) MS
2) Chronic Asthma
3) Beckers
4) other Neuro muscular diseases

Remember Share price is governed by future earnings

Diamond in the Spark Plus webinar gave us shareholders an insight into Atl 1102 possible earnings

CG in the video with AF said she was concerned at the SP
She also said VC and others wanted us “ to sell our souls” to raise $$$
AF was more excited with the prospects of Long Covid $$$

So you see people $5 is not so Ridiculous $$$$$